Compare HQL & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HQL | DNA |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 510.2M | 562.3M |
| IPO Year | N/A | N/A |
| Metric | HQL | DNA |
|---|---|---|
| Price | $17.19 | $9.21 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 120.9K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | N/A | ★ $180,606,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.28 |
| P/E Ratio | $17.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.34 | $5.00 |
| 52 Week High | $14.37 | $17.58 |
| Indicator | HQL | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 45.87 |
| Support Level | $16.86 | $8.56 |
| Resistance Level | $17.70 | $9.38 |
| Average True Range (ATR) | 0.39 | 0.53 |
| MACD | -0.04 | 0.26 |
| Stochastic Oscillator | 62.22 | 91.75 |
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.